Leadership & Pay ·
Entera Bio Ltd. announced on August 18, 2026, the appointment of Dr. Riccardo Paolo Camisasca as its new Chief Medical…
ENTXWEntera Bio Ltd.
Entera Bio Ltd. announced on August 18, 2026, the appointment of Dr. Riccardo Paolo Camisasca as its new Chief Medical Officer, effective immediately. Dr. Camisasca brings over 30 years of experience in clinical development and R&D leadership, most recently serving as Global Head of Research & Development at Sumitomo Pharma Switzerland. His appointment is intended to strengthen the company's clinical execution team ahead of the planned Phase 3 initiation for EB613, an oral anabolic treatment for osteoporosis. Entera Bio Ltd. operates in the biotechnology industry and develops oral peptide therapies.